Genome Repair Without Double-Strand Breaks: Mechanisms, Clinical Insights, and Therapeutic Advances

Abstract

Genome stability is essential for cellular health, and the repair of genetic lesions is a cornerstone of genomic integrity. While double-strand break (DSB) repair has been a central focus in genome editing and DNA repair research, emerging evidence highlights a diverse array of repair mechanisms that operate independently of DSBs. These pathways including base excision repair, nucleotide excision repair, mismatch repair, and single-strand template-mediated repair offer precise genomic correction with reduced risk of chromosomal rearrangement or cytotoxicity. This review evaluates the latest mechanistic insights, epidemiological relevance, diagnostic approaches, and therapeutic implications of DSB-independent genome repair, with emphasis on clinical translation, safety, and future innovations for healthcare professionals.

Introduction

DNA damage is a frequent occurrence, arising from endogenous metabolic byproducts, environmental mutagens, and medical interventions. The repair of such lesions is critical to prevent mutations, carcinogenesis, and inherited disorders. Traditional DNA repair research has centered on pathways that resolve DSBs the most lethal form of DNA damage. However, genome engineering and cellular biology have recently shifted toward exploring repair mechanisms that do not require DSB formation. These DSB-independent pathways have significant therapeutic potential, offering more controlled and less genotoxic strategies for genome correction. This article provides a comprehensive review of these mechanisms, their clinical applications, and evolving guideline recommendations.

Epidemiology / Disease Burden

The global burden of diseases linked to defective genome repair mechanisms is substantial, including various cancers, neurodegenerative disorders, and inherited syndromes such as Lynch syndrome and xeroderma pigmentosum. While DSB repair deficiencies are well recognized in these conditions, recent epidemiological data suggest that defects in DSB-independent repair pathways are also significant contributors to disease risk and progression. For example, mismatch repair deficiency is a defining feature of a subset of colorectal and endometrial cancers, affecting hundreds of thousands worldwide. The prevalence of single-nucleotide mutations and small insertions/deletions underscores the clinical need for precise, non-DSB-based therapeutic options.

Pathophysiology

DSB-independent genome repair encompasses several highly conserved pathways. Base excision repair (BER) corrects small, non-helix-distorting base lesions by excising damaged bases and filling in the gap with the correct nucleotide. Nucleotide excision repair (NER) removes bulky DNA adducts, such as those caused by UV radiation. Mismatch repair (MMR) corrects base mispairings arising during DNA replication. Recently, template-directed single-strand DNA repair, such as prime editing, has garnered attention for its ability to introduce precise genetic changes without generating DSBs. These pathways rely on specific endonucleases, polymerases, and ligases, and their fidelity is crucial for preventing mutagenesis and chromosomal instability.

Risk Factors

Genetic predispositions, such as inherited mutations in MMR genes (MLH1, MSH2, MSH6, PMS2), increase susceptibility to cancers and other disorders through impaired DSB-independent repair. Environmental exposures including UV light, alkylating agents, and oxidative stress can overwhelm these repair systems, leading to disease. Age-related decline in DNA repair efficiency and comorbidities such as chronic inflammation further increase the risk of genomic instability. Understanding these risk factors aids in identifying candidates for targeted therapies that leverage DSB-independent repair mechanisms.

Clinical Features

Clinically, defects in DSB-independent repair present with diverse phenotypes. Patients with MMR deficiency may develop multiple primary malignancies at a young age, while NER defects manifest as extreme sensitivity to sunlight and a high risk of skin cancers. Subtle repair deficiencies often manifest as increased somatic mutation rates, contributing to tumor heterogeneity or therapy resistance. Recognizing these features is essential for early diagnosis, surveillance, and intervention.

Diagnosis

Diagnostic evaluation of DSB-independent repair defects involves a combination of molecular assays and clinical criteria. Immunohistochemistry and microsatellite instability testing are routinely used to detect MMR deficiency in tumors. Genomic sequencing can identify pathogenic variants in BER and NER genes. Functional assays, such as in vitro DNA repair tests, provide direct evidence of pathway competency. Accurate diagnosis guides prognosis, therapeutic decision-making, and familial risk assessment.

Treatment & Management

Traditional management of diseases linked to defective genome repair includes surveillance, surgical intervention, and chemotherapeutic regimens tailored to the molecular defect. For example, patients with Lynch syndrome benefit from frequent colonoscopic screening and may be candidates for immunotherapy. Targeted therapies, such as PARP inhibitors, exploit specific repair deficiencies but are primarily used in DSB-deficient tumors. The emergence of genome editing tools particularly those that harness DSB-independent mechanisms offers new avenues for correcting pathogenic mutations with improved safety profiles and reduced risk of chromosomal aberrations.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable progress in DSB-independent genome editing technologies. Prime editing, a CRISPR-based approach, enables precise base conversions, insertions, and deletions by utilizing a reverse transcriptase fused to a catalytically impaired Cas9. This allows targeted DNA changes without generating DSBs or relying on donor templates. Base editors, which chemically modify single nucleotides, have demonstrated high efficiency and minimal off-target effects in preclinical models. These techniques are poised to revolutionize gene therapy for monogenic diseases, offering curative potential with reduced genotoxicity. Ongoing clinical trials are evaluating their safety and efficacy in hematological, ocular, and metabolic disorders.

Guideline Recommendations

Major professional organizations now recognize the importance of DSB-independent genome repair in both diagnostic and therapeutic contexts. Updated guidelines recommend molecular screening for repair deficiencies in patients with familial cancer syndromes and advocate for the inclusion of emerging genome editing techniques in clinical trial protocols. Ethical oversight and long-term follow-up remain paramount, given the novelty of these interventions. Continued collaboration between basic scientists, clinicians, and regulatory agencies will be critical to ensure the safe translation of these advances into routine practice.

Conclusion

DSB-independent genome repair mechanisms represent a paradigm shift in our understanding of genomic maintenance and therapeutic genome engineering. Their ability to correct pathogenic mutations with minimal collateral damage holds immense promise for precision medicine. Ongoing research and innovation in this field will likely expand the repertoire of treatable genetic diseases, improve patient outcomes, and redefine standards of care for hereditary and acquired disorders linked to genome instability.